• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Lidocaine Injection or Cream for Vulvar Biopsy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Williams et al. (Obstetrics & Gynecology, 2020) compared application of lidocaine–prilocaine cream vs lidocaine injection for pain control during vulvar biopsy

METHODS:

  • Single-site randomized trial (RCT)
  • Participants
    • Undergoing vulvar biopsy
    • Non–hair-bearing surface
  • Interventions
    • Lidocaine–prilocaine cream 5% (Eutectic Mixture of Local Anesthetics [EMLA]) | 5 g placed ≥10 minutes prior to procedure
    • Lidocaine injection 1% | 2 ml injected using a 27 guage needle ≥1 minute prior to procedure
  • Study design and data analysis
    • Pain was recorded using a 100 mm visual analog scale | 0 mm = no pain and 100mm = worst imaginable pain
    • 3 time points: Baseline | After application of anesthesia | After biopsy
  • Primary outcome
    • Highest pain score recorded
  • Secondary outcomes
    • Pain score at biopsy
    • Patient experience
    • Tolerability and acceptability
  • Statistical analysis – Power and sample size
    • 90% power | Two-sided alpha level of 0.05
    • To detect a 16 mm difference with (SD of 25 mm), sample size of 53 participants required in each treatment arm

RESULTS:

  • 37 patients included (trial stopped at interim analysis due to difference in pain scores between groups in favor of cream group)
    • Participant median age was 60 years
    • 19 were randomized to the lidocaine–prilocaine group, 18 to the lidocaine injection group
  • Median highest pain score
    • Cream group: 20.0 mm
    • Injection group: 56.5 mm
  • Controlling for baseline pain: Cream group experiencing a 25.7 mm lower pain score than injection (95% CI, −45.1 to −6.3; p<0.01)
  • Reduced pain scores in cream group vs injection still documented when number of biopsies taken in to account
  • Overall median patient experience score also favored cream group (p=0.02)
    • Cream: 2.0 mm
    • Injection group: 17.0 mm
  • The difference in pain is perceived prior to biopsy rather than actual biopsy

CONCLUSION:

  • In this study group, women who received topical lidocaine–prilocaine cream before vulvar biopsy had a lower maximum pain score and rated their experience better than women who received lidocaine injection
  • The authors suggest

Lidocaine–prilocaine cream, alone, should be considered as an anesthetic method for vulvar biopsy in a non–hair-bearing area on an individualized basis after an informed discussion between patients and health care providers.

Learn More – Primary Sources:

Lidocaine–Prilocaine Cream Compared With Injected Lidocaine for Vulvar Biopsy: A Randomized Controlled Trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Vulvar Intraepithelial Neoplasia (VIN): Diagnosis and Treatment 
Does Self-Administered Lidocaine Gel Reduce Pain During IUD Insertion?
Can lidocaine gel replace paracervical block for gyn procedures?
Reducing Pain During Office Hysteroscopy: Voltaren vs Buscopan

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site